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A growing body of evidence indicates that PPAR (peroxisome proliferator-activated receptor) α agonists might have therapeutic
usefulness in antitumoral therapy by decreasing abnormal cell growth, and reducing tumoral angiogenesis. Most of the anti-
inﬂammatoryandantineoplasticpropertiesofPPARligandsareduetotheirinhibitoryeﬀectsontranscriptionofavarietyofgenes
involved in inﬂammation, cell growth and angiogenesis. Cyclooxygenase (COX)-2 and vascular endothelial growth factor (VEGF)
are crucial agents in inﬂammatory and angiogenic processes. They also have been signiﬁcantly associated to cell proliferation,
tumor growth, and metastasis, promoting tumor-associated angiogenesis. Aberrant expression of VEGF and COX-2 has been
observed in a variety of tumors, pointing to these proteins as important therapeutic targets in the treatment of pathological
angiogenesis and tumor growth. This review summarizes the current understanding of the role of PPARα and its ligands in the
regulation of COX-2 and VEGF gene expression in the context of tumor progression.
Copyright © 2008 Raquel Grau et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear receptor family of transcription
factors. They modulate gene transcription in response to
speciﬁc ligands by binding as heterodimers with the retinoid
X receptor (RXR) to a speciﬁc peroxisome proliferator-
response element (PPREs) on target genes (reviewed in [1,
2]). Three distinct isoforms of PPARs have been described
PPAR α, β/δ,a n dγ,e a c he n c o d e db yad i ﬀerent gene
and showing a distinct tissue distribution [3]. Originally
found to be involved in the regulation of lipid and glucose
metabolism, [4, 5] interest in these receptors has increased
dramatically as a consequence of recent studies showing
their involvement in tumoral cell growth and inﬂammation
(reviewed in [6–9]). Therefore, in addition to their well-
known eﬀects in diabetes and hyperlipidemic disorders,
pharmacological agents that target PPARs may have thera-
peutic applications in inﬂammatory diseases and cancer.
PPARα was the ﬁrst PPAR identiﬁed [10]. It has a wide
tissue distribution being expressed in liver, skeletal muscle,
intestine, kidney, adipose tissue, and vascular endothelial
cells, tissues in which fatty acids are predominantly catab-
olized [11, 12]. Several ligands have been shown to bind
PPARαandtoregulatetranscriptionalactivityoftargetgenes
involved in the regulation of fatty acid metabolism as fatty
acid transporters, catabolic enzymes involved in mitochon-
drial, and peroxisomal oxidation as well as genes necessary
for the maintenance of redox balance during the oxidative
catabolism of fatty acids [4, 5, 13]. PPARα-activating ligands
include a number of pharmacological compounds as well
as fatty acid and fatty acid-derived molecules (reviewed
in [2]). Lipid-lowering ﬁbrates as Bezaﬁbrate, Cloﬁbrate,
Fenoﬁbrate and Gemﬁbrozil as well as certain nonsteroidal
anti-inﬂammatorydrugs(NSAIDs)bindandactivatePPARα
[14, 15]. In addition, a variety of unsaturated and saturated
fatty acids including arachidonic acid, palmitic acid, linoleic
acid, linolenic acid, and oleic acid can act as natural ligands
of PPARα as they can bind and activate this receptor. Some
eicosanoidsderivedfromthemetabolismofarachidonicacid
such as leukotrienes (LTs), hydroxyeicosatetraenoic acids
(HETEs), and prostaglandins (PGs) can also be eﬀective2 PPAR Research
ligandagonistsforspeciﬁcPPARisoforms[16–19].However,
it is not clear whether the concentrations at which binding of
these compounds occurs are physiologically relevant.
In addition to its known role in the regulation of genes
involved in fatty acid metabolism, this isoform has been
shown to attenuate the inﬂammatory response [6, 7, 9].
Most recently, an antitumoral role of PPARα and its ligands
has been proposed [7, 8]. This assumption is supported
by recent experimental evidence, revealing antitumoral and
anti-angiogenic properties of PPARα activators both in vitro
and in vivo.
2. ANTI-INFLAMMATORY ACTIONS OF PPARα
In recent years, considerable attention has focused on the
involvement of PPARs in inﬂammatory processes. Anti-
inﬂammatory eﬀects of PPAR ligands, in particular those
of PPARα and PPARγ, have been ascribed to inhibition of
the expression of inﬂammatory genes and negative interfer-
ence with pro inﬂammatory transcription factor signaling
pathways in vascular and inﬂammatory cells (reviewed in
[1, 6, 20]. The ﬁrst evidence for the involvement of PPARα
in the control of inﬂammation came from the studies of the
inﬂammatory response elicited by LTB4 in PPARα deﬁcient
mice. In these animals, inﬂammatory response to LTB4
was prolonged compared to WT mice, correlating with the
ability of LTB4 to activate PPARα and regulate the expres-
sion of genes involved in its own catabolism [21]. Thus,
proinﬂammatory lipid metabolites may serve as ligands
for PPARs thereby activating PPARα responsive enzymes
responsible for their clearance. Therefore, some of the anti-
inﬂammatory actions of these receptors can occur through
this autoregulatory loop in lipid homeostasis. Several lipids
mediators, as the polyunsaturated fatty acids (PUFAs), can
function as ligands for PPARs [2]. Arachidonic acid is a
precursor of several eicosanoids that have pro inﬂammatory
properties whereas the ω-3 PUFAs are precursors of anti-
inﬂammatoryeicosanoidsasEPA(eicosapentanoidacid)and
docosahexaenoic acid (DHA). These ω-3 PUFAs derivatives
have been reported to decrease the production of several
pro inﬂammatory cytokines, having beneﬁcial eﬀects in
several inﬂammatory diseases as rheumatoid arthritis and
inﬂammatory bowel disease [22, 23].
Several studies have conﬁrmed the anti-inﬂammatory
properties of PPARs in vitro and in vivo through the regu-
lation of genes involved in the inﬂammatory response. PPAR
agonists decrease plasma concentrations of interleukin (IL)-
6, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ in
humans [24, 25]. In vascular smooth-muscle cells, PPARα
ligands inhibit IL-1-induced production of IL-6, COX-2,
andprostaglandins[25].PPARαactivationinhibitscytokine-
induced expression of vascular cell-adhesion molecule-1
(VCAM-1) and vascular endothelial growth factor receptor-
2 (VEGFR-2) in endothelial cells [26, 27]. PPARα have been
alsoinvolvedinthedownregulationoftheproductionofIL-2
and TNFα by T lymphocytes [28].
At the molecular level, most of the inhibitory actions of
PPARα on gene transcription result from its ability to tran-
srepress the activities of many activated transcription factors
such as nuclear factor (NF)-κB[ 25, 29], activator protein-
1 (AP-1) [29, 30] C/EBPβ [31, 32], signal transducers and
activators of transcription (STATs) [33], and transcription
factorspeciﬁcityprotein1(Sp-1)[27].Negativeregulationof
gene expression by PPARα can occur by several mechanisms
(Figure 1).ActivatedPPAR-RXRcomplexesmaycompetefor
limited amounts of essential coactivators shared with other
transcription factors. Direct physical interactions between
PPARs and speciﬁc transcription factors have been also
proposed to mediate transcriptional inhibition by activated
PPARα, resulting in reduced binding to their cognate
response elements. Agonists-activated PPARα can eﬀectively
antagonize NF-κB and AP-1-mediated signaling pathways in
a bidirectional manner by physical interaction with the Rel
homologydomainofNFκB-p65andwiththeaminoterminal
of c-Jun, respectively [34]. Physical association of the C-
terminal DNA binding region of c/EBPβ with PPARα medi-
ates inhibition of alpha1-acid glycoprotein gene expression
[31]. PPARα agonists can also inﬂuence transcriptional
activation by modulating the expression of transcriptional
repressors such as IκBα (Kleemann, 2003 #1223; Vanden
Berghe, 2003 #2170}). Finally, an additional mechanism of
transrepression relies on the ability of some PPARα ligands
to interfere with the activation of certain members of the
mitogen-activated protein kinase (MAPK) cascade as Jun
kinase (JNK) and p38 MAPK [30, 35, 36].
3. INVOLVEMENT OF PPARα IN CANCER
Rapidly accumulating evidence links members of the PPAR
family and their agonists to cellular growth and tumor
progression. The role of the PPARγ isotype in cancer
has been widely studied with a large number of reports
demonstrating antitumoral properties of PPARγ agonists in
a variety of diﬀerent malignancies [8]. Concerning to the
involvement of the PPARα form and its ligands in cancer,
both tumor promotion and suppression properties have
been reported [37]. Sustained PPARα activation by agonists
as cloﬁbrate and Wy-14643 induce hepatocarcinogenesis
in rodents [38, 39]. However, epidemiological data on
long-term administration of PPARα activators in the clinic
discard the occurrence of these eﬀects in human [40–43].
Discrepancies on the eﬀects of PPARα ligands in rodents and
human liver seem to be due to several diﬀerences between
species [44]. PPARα mediated signaling is less eﬃcient in
human than in mice [37, 43, 45] and expression of this
receptor is 10 to 20 times higher in rodent hepatocytes
compared to human liver [46].
Emerging evidence indicates that PPARα ligands are
able to suppress the growth of diﬀerent types of human
carcinomas. PPARα is expressed in a variety of human
and murine tumor cell lines [47–49]. Expression of PPARα
have been also reported in clinical samples of several types
of human cancers as colorectal carcinoma [50], prostate
adenocarcinoma, [47, 51], testicular cancer [52], bladder
carcinoma [53], and medulloblastoma [54]. PPARα ligands
are able to arrest the growth of human cancer cell lines
in vitro and to slow the growth of transplanted human
tumor cells in nude mice. These anticancer eﬀects have beenRaquel Grau et al. 3
(1) (2) (3) (4)
RXR PPAR
Lig
MAPK
Transc
factor
Transc
factor
Transc
factor
Transc
factor
Co-activators Repressor
P Gene
transcription
Figure 1: Negative regulation of gene expression by PPARs. Diﬀerent mechanisms of transrepression through interference of activated PPARs
with activation of transcription factors have been described. (1) Activated PPAR-RXR complexes may sequester essential coactivators shared
with other transcription factors. (2) Physical association of PPARs with speciﬁc transcription factors results in reduced binding to their
cognateresponseelements.(3)PPARαagonistscanalsoinﬂuencetranscriptionalactivationbyupregulatingtheexpressionoftranscriptional
repressors such as IκBα.( 4 )P P A R α-mediated interference on the activation of members of the mitogen-activated protein kinase (MAPK)
cascade inﬂuences transcription factor activation.
observed in several diﬀerent cancer cell types including hep-
atoma [55], melanoma [56], glioblastoma and ﬁbrosarcoma
[49], endometrial and ovarian cancer [57–59], as well as
colon carcinoma [50, 60, 61]. Cloﬁbric acid, a ligand for
PPARα inhibits growth of ovarian cancer both in vivo and in
vitro [58, 59]. Mice treated topically with the PPARα ligand
Wy-14643 exhibited diminished skin tumorigenesis [62].
Moreover, Fenoﬁbrate suppresses the metastatic potential of
melanoma cells [56, 63].
Even though accumulative evidence shows data suggest-
ing that PPARα ligands may display antitumoral properties,
theprecisemechanismremainsunclear.Anumberofreports
suggest that antitumor properties of PPARα activators reside
on their anti-inﬂammatory and anti-angiogenic eﬀects [27,
64,65](Figure 2).ThedependenceonthepresenceofPPARα
for the antitumorigenic and anti-angiogenic role of PPAR
ligands has been determined by the analysis of their eﬀects
in PPARα null mice. Wy-14643-mediated antitumoral and
anti-angiogenic responses on tumor and endothelial cells are
absent in PPARα KO mice [66]. Panigrahy and coworkers
[49] have shown the importance of the microenvironment
in tumor progression in such a way that the activation
of PPARα expressed in endothelial and inﬂammatory cells
of the host rather than in the tumoral cells is critical for
anti-inﬂammatory, antitumor and anti-angiogenic activity
of PPARα agonists. Consistent with the anti-inﬂammatory
role of this receptor, PPARα null mice exhibit an increase
of inﬂammatory inﬁltrates in tumors. Paradoxically, in spite
of the enhanced inﬂammatory response in the absence of
PPARα, tumor growth is suppressed in these animals as a
consequence of an increased production of anti-angiogenic
factors TSP-1 and endostatin [67]. The immune system
c a nh a v eam u l t i t u d eo fe ﬀects on cancer development and
progression, both favorable and detrimental [68, 69]. This
apparent contradiction has been explained by the severity
and duration of the inﬂammatory response associated to
tumor growth. While acute inﬂammation is part of the
defenseresponsethatmayparticipateintheremissionofpre-
clinical cancers, chronic inﬂammation can promote tumor
development with inﬁltrating innate immune cells provid-
ing proinﬂammatory and proangiogenic factors including
cytokines, chemokines, VEGF, and prostanoids [70–72]. The
association between cancer and inﬂammation has been also
illustrated by epidemiological studies showing that the use
of anti-inﬂammatory compounds in chronic inﬂammatory
diseases reduces cancer risk tumor [73, 74]. In this sense,
PPARα-mediated anti-inﬂammatory actions can be respon-
sible for their potential chemopreventive eﬀects in tumor
progression.
An emerging area of interest is the association of anti-
inﬂammatory actions of dietary PUFAs as potential natural
agonists of PPARs with cancer risk. Increasing evidence sug-
gests that dietary fat regulation of gene expression can play a
critical role in initiation and progression of human cancer
and epidemiological studies have suggested an association
between dietary fat and cancer risk [75, 76]. A number of
reports have shown the beneﬁcial eﬀects of consumption
of ω-3 PUFAs, associated with anti-inﬂammatory eﬀects
and with protection against primary tumor development
[22,23,75].Althoughsomeoftheeﬀectsofdietarylipidscan
be linked to PPARs-mediated signaling, additional research
is needed to understand the potential connection between
dietary fat intake and PPARs in the control of inﬂammation
and tumor progression.4 PPAR Research
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Figure 2: Antitumoral eﬀects of PPARα ligands. Tumor progression depends on a cascade of cellular signals involving: (a) proinﬂammatory
factors (cytokines, COX-2 derived prostaglandins (PGs), chemokines); (b) proangiogenic factors (VEGF, bFGF, and PGs) produced by
endothelial and inﬂammatory cells, stromal ﬁbroblasts, and tumor cells. These factors promote cell proliferation, migration, and induce new
vessels that deliver nutrients and oxygen to the malignant cells and therefore allow tumor growth and metastasis. PPARα ligands may display
antitumoral properties by their inhibitory eﬀects on the transcription of genes involved in inﬂammation, cell growth, and angiogenesis thus
leading to the inhibition of tumor growth.
Table 1: Eﬀects of PPARα ligands on COX-2 signaling.
PPARα ligand Action/eﬀect References
Wy-14643
Inhibition of IL-1-induced COX-2 expression in vascular smooth muscle cells [25]
Inhibition of LPS-induced COX-2 expression in THP-1 monocytes [94]
Inhibition of TPA-induced COX-2 expression in colon carcinoma cell lines [30]
Inhibition of COX-2 expression in B16-F10 melanoma tumor [49]
Inhibition of COX-2 up regulation by experimental steatohepatitis in liver [95]
Fenoﬁbrate
Inhibition of COX-2 expression in B16-F10 melanoma tumor [49]
Inhibition of b-FGF induced COX-2 expression in endothelial cells [65]
Cloﬁbric acid
Inhibition of COX-2 expression in tumor xenografts [58]
Inhibition of mPGES-1 expression in tumor xenografts [59]
4. PPARα, COX-2, AND CANCER
4.1. COX-2:anessentialroleininﬂammationand
tumorgrowth
Cyclooxygenases (COX-1 and COX-2) convert arachidonic
acid to prostaglandin H2(PGH2), an endoperoxide inter-
mediate that, via speciﬁc synthases, is then transformed to
prostaglandins (PGE2,P G D 2,P G F 2α,P G I 2) and thrombox-
anes (TXA2). Whereas COX-1 is constitutively expressed
in most tissues, COX-2 is transcriptionally upregulated in
response to mitogens, tumor promoters, and pro inﬂamma-
tory stimuli in a discrete number of cell types (reviewed in
[77–79]). These enzymes are the target of nonsteroidal anti-
inﬂammatory drugs (NSAIDs), one of the most widely used
therapeuticforthereliefofpainandinﬂammation(reviewed
in [80–82]). The anti-inﬂammatory and analgesic eﬃcacy
of drugs arises essentially from inhibition of the enzymatic
activity of COXs. As COX-2 is though to be the predominant
isoform involved in the inﬂammatory response, the ability
of NSAIDs to inhibit COX-2 activity may explain their
therapeutic eﬀects as anti-inﬂammatory drugs. Therefore,
most of the new research on anti-inﬂammatory drugs has
been aiming at targeting the COX-2 inducible production of
PGs.
Inaddition toitsessentialroleininﬂammation,accumu-
lating evidence links COX-2 with cancer and angiogenesis,
suggestingthatdrugsthattargetCOX-2andrelatedsignaling
cascades could be used as antitumoral agents [74]. Many
human cancers display elevated COX-2 expression and
studies in COX-2 null mice have demonstrated the role of
this enzyme in tumor progression and metastasis [83–85].Raquel Grau et al. 5
Table 2: Eﬀects of PPARα ligands on VEGF signaling.
PPARα ligand Action/eﬀect References
Wy-14643
Inhibition of VEGF-mediated endothelial cell migration [27, 49, 64]
Inhibition of VEGF production by glioblastoma U87 cells [49]
Inhibition of VEGF-induced phosphorylation of Akt [64]
Inhibition of VEGF-mediated angiogenesis in vitro [27]
Fenoﬁbrate
Inhibition of VEGF production by glioblastoma U87 cells [49]
Reduction of plasma VEGF [96]
Inhibition of VEGF-induced phosphorylation of Akt [64]
Inhibition of VEGFR2 expression in endothelial cells [27]
Cloﬁbric acid
Inhibition of VEGF expression in tumor xenografts [58]
Moreover, epidemiological studies have revealed a role
of selective COX-2 inhibitors in decreasing the risk of
developingcoloncancerandinsuppressingtumorformation
and growth in animal models [73, 86–88]. COX-2 inhibitors
can block both the production of angiogenic factors and the
migration of vascular endothelial cells, and thus decrease
tumor growth [89, 90]. Although some of the eﬀects of these
drugs on tumor regression might result from modulation of
COX-2-independent pathways [91], it is likely that COX-2 is
an important mediator of tumor growth.
4.2. EffectsofPPARαligandsonCOX-2expression
The activity of COX-2 is closely linked to PPARs as
COX-2 catalyzes the production of fatty acid derivates
as prostanoids that are PPAR activators [2]. Modulation
of COX-2 activity should inﬂuence the local availability
of PPAR ligands; therefore, indirectly modulating PPAR
activity. Moreover, some NSAIDs may act as PPARα and γ
ligands, suggesting that, in addition to inhibit prostaglandin
production, they might regulate gene expression as part of
their anti-inﬂammatory and chemopreventive mechanisms
[92, 93]. Downregulation of COX-2 expression by PPARα
ligands may account for some of the anti-inﬂammatory,
anti-angiogenic and antitumoral properties of these drugs
in a variety of cell types [20]( Table 1). PPARα agonists
as Wy-14643 inhibit macrophage diﬀerentiation and COX-
2 gene expression [94]. In liver, COX-2 upregulation upon
experimental nutritional steatohepatitis is suppressed by the
PPARα agonist Wy-14,643 in wt but not in PPARα KO
mice. This eﬀect has been ascribed to the ability of activated
PPARα to interfere with the NF-κB-signaling pathway [95].
Transcriptional interference of activated PPARα with NF-
κB also explains the inhibition of COX-2 induction and PG
production in response to IL-1 in vascular smooth muscle
cells [25]. The NF-κB target genes VCAM-1 and COX-2
are also downregulated by PPARα ligands in response to
cytokine activation [29]. Regarding to experimental support
for anti-angiogenic and antitumoral actions of these drugs
related to their eﬀects on COX-2 expression, it has been
shownthatFenoﬁbrateinhibitsbFGF-mediatedangiogenesis
and COX-2 mRNA expression in endothelial cells [65].
Panigrahy and cols have observed suppression of COX-2
expressioninFenoﬁbrateandWy-14643treatedtumors[49].
Cloﬁbric acid suppresses the growth of tumor xenograts of
ovarian cancer cell lines with decreased microvessel density,
PGE2 production, and COX-2 and mPGES-1 expression
[58, 59]. Diminished expression of COX-2 upon PPARα
agonist treatment was parallel with reduced expression of
AP-1. Similarly, in colon carcinoma cells, PPARα agonists
severely diminish phorbol ester-mediated AP-1-dependent
induction of COX-2 expression [30].
5. PPARα, VEGF, AND CANCER
5.1. VEGF:atherapeutictargetin
tumoralangiogenesis
Angiogenesis, deﬁned as the formation of new blood vessels
from preexisting vasculature, occurs under physiological
conditions during embryonic development and is required
for wound healing and reproduction in the adult. Indis-
pensable for physiological processes, angiogenesis is highly
regulated via ﬁne tuning of the balance between pro- and
anti-angiogenic factors [97]. Excessive angiogenesis is tightly
linked to human disease, including chronic inﬂammatory
disease, diabetic retinopathy, and cancer [98, 99]. Ample
evidence shows that blockade of tumoral angiogenesis often
relieves the severity of cancer [100].
Both cancer cells and cells attracted to the sites of
inﬂammation are able to produce proangiogenic factors
that cause endothelial cell recruitment and proliferation for
the supply of oxygen and nutrients that favor the growth
of solid tumors and facilitate metastasis. In this context,
tumor-associated hypoxia plays an essential role in the
regulation of angiogenesis [101]. Response to hypoxia is
mediatedbymembersofthehypoxia-inducibletranscription
factors (HIFs) involved in the regulation of the expression
of genes participating in oxygen homeostasis [102, 103]. In
addition, hypoxia has been also found to drive induction6 PPAR Research
of potent angiogenic and inﬂammatory factors including
VEGF, VEGF-R1 and -R2, angiotensin, metalloproteinases,
and COX-2 [104–106]. This response of tumors to hypoxia
contributes to the malignant phenotype and to more aggres-
sive tumor progression [107].
It has been well established that VEGF signaling pathway
is one of the key regulators in angiogenesis [108, 109].
Cytokines, growth factors, tumor promoters, and hypoxia
modulate the expression of VEGF [110, 111]. Activated
VEGF may bind to two types of tyrosine kinases receptors:
VEGFR-1 and VEGFR-2. Proangiogenic actions of VEGF as
vascular endothelial cell permeability, proliferation migra-
tion, and survival are mediated mainly through binding
an activation of the VEGFR-2 [112, 113]. Accumulating
evidence supports a key role of VEGF in cancer, contributing
to tumor neovascularization and dissemination. Increased
expression of this factor has been found in most tumors,
and agents neutralizing VEGF expression or activity inhibit
t u m o rg r o w t hi nv i v o( r e v i e w e di n[ 99, 100, 114]).
5.2. InhibitionofVEGFsignalingbyPPARαagonists
PPARα ligands can inhibit endothelial cell proliferation and
migration and induce endothelial cell apoptosis in vitro,
suggesting an important role of this receptor in tumor
angiogenesis. Part of these eﬀects occurs through the ability
ofPPARαligandstointerferewithVEGF-mediatedsignaling.
(Table 2). At the transcriptional level, PPAR agonists have
been shown to inhibit endothelial VEGFR-2 expression
by repressing transactivation and binding of Sp1 to DNA
[27]. Wy-14643 downregulates TPA-mediated transcrip-
tional induction of VEGF by interference with activation
of AP-1 [30]. Interestingly, lipid-lowering therapy with
Fenoﬁbrate induces a signiﬁcant reduction of VEGF levels in
serum [96]. Anti-angiogenic actions of PPARα agonists may
explainsomeoftheirantitumoraleﬀects.Fenoﬁbratereduces
adventitial angiogenesis and inﬂammation in a porcine
model of coronary angioplasty [115]. Both Fenoﬁbrate
and Wy-14643 are able to suppress VEGF secretion in
glioblastoma cells and Lewis lung carcinoma cells and to
inhibitangiogenesisbothinvivoandinvitro[49].Moreover,
Cloﬁbric acid inhibits VEGF expression in tumor xenografts
of ovarian cancer cell lines with a reduction in angiogenesis
and decreased microvessel density in solid tumors [58, 59].
6. CONCLUSIONS
Taken together, ﬁndings on the eﬀects of PPARα ligands in
inﬂammationandcancer,suggestthatPPARαactivationmay
be beneﬁcial against tumorigenesis through the inhibition of
transcriptional activation of genes involved in inﬂammation
and angiogenesis such as COX-2 and VEGF. Although
COX-2 and VEGF are one of the many proinﬂammatory
and proangiogenic factors that drive tumor growth and
metastasis, targeting these proteins suﬃces to signiﬁcantly
impair tumor growth and angiogenesis. Inhibition of tumor
inﬂammation and tumor angiogenesis by PPARα ligands
might be responsible for their potential chemopreventive
eﬀects in a variety of experimental models of cancer.
However, it must be taken into account that many of the
reported eﬀectsofPPARαligandsontumorprogressionhave
been obtained in vitro and await conﬁrmation by additional
basic and clinical research to ascertain whether they can be
considered of pharmacological signiﬁcance in vivo.
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